Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking ...

Obesity drug developer BioAge Labs (BIOA) files for U.S. IPO to offer 7.5M shares at $17-$19 implying valution of up to $602M ...

Healthcare firms have done comparatively well in an otherwise subdued U.S. IPO market in 2024, which analysts touted as a comeback year for public offerings. The Richmond, California-based company ...

BioAge will use the proceeds from the initial public offering to move its oral apelin receptor agonist azelaprag past its ...

BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 ...

NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

A Quick Take On BioAge Labs, Inc. BioAge Labs, Inc. (BIOA) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information. The company is a clinical ...

Biopharmaceutical start-up BioAge Labs is developing a weight loss drug for older adults known as azelaprag, which is ...

RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc. (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the ...